Agilent J&W continues their ultra inert innovations with the new DB-35ms Ultra Inert GC column --- a mid-polar column joining the existing apolar columns in the family, DB/HP-1ms and DB/HP-5ms.
Put 40 years of Agilent quality and innovation behind your every separation. Agilent J&W Ultra Inert GC columns push the industry standards for consistent column inertness and exceptionally low column bleed, resulting in lower detection limits and more accurate data for difficult analytes. These columns are tested with the most demanding Ultra Inert test probe mixture in the industry, and a performance summary sheet is shipped with each column. So you will see specific proof of performance, and proof of inertness, unique to every column you receive.
New member of Ultra Inert family offers enhanced selectivity
With the addition of this new column to the family, ultra inert performance is available for applications where different (mid-polar) selectivity is needed for enhanced separations, especially important for pesticide analysis and drugs of abuse testing. So chemists can quantify components at a lower level, have broader linearity, and optimize their separation by choosing the right selectivity…ultimately increasing their productivity.
Learn more and download your copy of the Agilent J&W DB-35ms Ultra Inert GC Column flyer now.
LC–MS/MS Quantification of Plasma Proteins in Elephant Seals to Advance Wildlife Conservation
November 12th 2024Liquid chromatography and tandem mass spectrometry (LC–MS/MS) was used to show that repeated stress can cause delayed but sustained changes in blood plasma proteins associated with water conservation, immune responses, fat metabolism, insulin sensitivity, iron recycling, and hormone transport in elephant seals. Some of these changes may be novel markers of recent and chronic stress exposure in marine mammals.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.